Trials / Completed
CompletedNCT00900016
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
Pharmacodynamic Study of Fibroblast Activity Protein in Patients With Localized Pancreas Cancer Undergoing Surgical Resection
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 37 (actual)
- Sponsor
- Fox Chase Cancer Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is assessing fibroblast activity in patients with localized pancreatic cancer undergoing surgery.
Detailed description
OBJECTIVES: Primary * To assess the degree of fibroblast activation protein (FAP) enzymatic activity at the tumor site in patients with localized pancreatic cancer. Secondary * To explore correlations between tumor stromal FAP enzymatic activity and stromal α\_2-antiplasmin levels. * To explore correlations between tumor FAP enzymatic activity and plasma dipeptidyl peptidase and plasma α\_2-antiplasmin converting enzyme activity as potential surrogates. OUTLINE: Patients undergo fine-needle aspiration of tumor or suspected mass at baseline. Tumor samples are analyzed by IHC for fibroblast activation protein (FAP) expression, immunocapture assay for ex vivo FAP enzymatic activity, and western analysis for FAP concentrations. Blood samples are collected weekly and analyzed for dipeptidyl peptidase activity by ELISA and α\_2-antiplasmin converting enzyme.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | protein expression analysis | |
| GENETIC | western blotting | |
| OTHER | immunohistochemistry staining method | |
| OTHER | immunologic technique | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2013-12-01
- Completion
- 2017-06-23
- First posted
- 2009-05-12
- Last updated
- 2017-09-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00900016. Inclusion in this directory is not an endorsement.